Discover All Perspectives.
Published loading...Updated

Biocurious: Forgotten trans-Tasman 'small Big Pharma' takes on the big boys with a niche strategy

Summary by Stockhead
AFT Pharmaceuticals has zeroed in on multiple diseases the big pharma plays don’t bother with – but can be highly profitable AFT has targeted boosting its revenue from NZ$200 million to NZ$300 million within the next two years Some AFT investors are tetchy about substandard returns, but co-founder Hartley Atkinson insists the company is focused on long-term growth   When Dr Hartley Atkinson and his nurse wife Marree founded AFT Pharmaceuticals (…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Stockhead broke the news in on Tuesday, May 27, 2025.
Sources are mostly out of (0)